Monrovia's Xencor Reports $32.8 Million Third Quarter Loss

Monrovia's Xencor Inc. has  reported a $32.8 million loss in its third quarter, or a loss of 55 cents per share. The company develops "engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases." t.ly/pI-k

- Brad Haugaard